Craft

TELA Bio

Stock Price

$2.9

2024-10-29

Market Capitalization

$113 M

2024-10-29

Revenue

$80.3 M

FY, 2025

TELA Bio Summary

Company Summary

Overview
TELA Bio is a medical technology company focused on designing, developing and marketing tissue reinforcement materials to address the needs in soft tissue reconstruction. The company offers a range of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.
Type
Public
Status
Active
Founded
2012
HQ
Malvern, PA, US | view all locations
Website
http://telabio.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Antony Koblish

    Antony Koblish, Co-founder, President, Chief Executive Officer

  • E. Skott Greenhalgh

    E. Skott Greenhalgh, Chief Technology Officer

  • Matt Zuga, Director

    • Greg Firestone

      Greg Firestone, Vice President, Strategic Customer Relations

      Operating MetricsView all

      Patients Enrolled

      32

      Jun, 2019

      Surgeons Collaborated

      100

      Jun, 2019

      LocationsView all

      1 location detected

      • Malvern, PA HQ

        United States

        1 Great Valley Parkway, Suite 24

      TELA Bio Financials

      Summary Financials

      Revenue (Q1, 2026)
      $19.1M
      Gross profit (Q1, 2026)
      $12.5M
      Net income (Q1, 2026)
      ($12.3M)
      Cash (Q1, 2026)
      $39.5M
      Enterprise value
      $129.4M

      Footer menu